TNI BioTech Inc. TNIB Archives

ThursdayDec 27, 2012 2:14 pm

Umbrella Research Initiates Coverage on TNI BioTech, Inc. (TNIB) and Sets $26 Price Target

Earlier today, TNI BioTech, a biotech company focused on utilizing patented immunotherapy to activate and mobilize the body’s immune system to combat fatal diseases, announced that Umbrella Research is now covering the company with a “buy” rating and $26 price target. The entire 33-page report has been posted on the company’s Web site at http://www.tnibiotech.com/investor-relations/reports The following is an excerpt of the report: “It is our opinion that TNI presents investors with significant upside from current prices based on a two-fold growth strategy including: the near term commercialization of its existing immunotherapies targeting cancer and HIV/AIDS; coupled with the potential…

WednesdayNov 28, 2012 5:01 pm

TNI BioTech, Inc. (TNIB) and Immunotherapy

Just as stem cell technology holds out the current best hope for the regeneration of healthy cells, immunotherapy is becoming the latest best hope for efficiently dealing with diseased cells. Although immunotherapy in its broadest form can be said to date back to the pioneering work of 18th century English physician Edward Jenner, who greatly advanced the ancient but dangerous practice of inoculation, the modern practice of manipulating the body’s own immune system to treat disease is often marked by American surgeon William Coley who developed a rudimentary cancer treatment based on provoking an immune response to bacteria around 1891.…

WednesdayNov 21, 2012 5:58 pm

TNI BioTech, Inc. (TNIB) Goes After the Magic Bullet

TNI BioTech is combating fatal diseases by using the developing science of immunotherapy. By learning how to activate and manipulate the body’s own immune system, TNI has developed their own patented immunotherapy that promises new and better options for the treatment of cancer and infections such as HIV and autoimmune diseases. TNI’s most advanced clinical programs involve immunotherapy that isolates a patient’s lymphocytes and then incubates them together with Methionine Enkephalin (MENK). The lymphocytes are then reinfused back into the patient where they combat and destroy tumor cells. A primary target for immunotherapy is cancer, and it’s an approach that…

ThursdayNov 15, 2012 6:34 pm

TNI BioTech, Inc. (TNIB) Enters Exclusive Distributor Agreement with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC

Today, shortly before the opening bell, TNI BioTech announced that it has signed an exclusive distributor agreement with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC for the Federal Republic of Nigeria. As a result, G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC will have exclusive marketing and distribution rights to IRT-103 LDN and IRT-104 LDN cream in Nigeria. TNIB will be responsible for the manufacture and supply of IRT-103 LDN and IRT-104 LDN cream. The therapies, developed as a treatment for cancer, HIV/AIDS, and other autoimmune diseases, are to be manufactured in the company’s facility in Managua,…

MondayNov 12, 2012 6:52 pm

TNI BioTech, Inc. (TNIB) Helps Lead the Way to a New Africa

When TNI BioTech recently signed an agreement to open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital in Malawi, in southwestern Africa, it reflected an ongoing change in the attitude of the industrialized world toward Africa. Once largely ignored because of its troubled political history and lack of infrastructure and technology, Africa is suddenly rising on the world’s economic radar. The second largest land mass on the globe, with the second largest population of any continent, Africa has been seeing rapid economic growth, and has been compared to Asia in its potential. In a Seeking Alpha article,…

MondayNov 05, 2012 11:21 am

TNI BioTech, Inc. (TNIB) Capitalizes on Rich Pharmaceutical Experience

TNI BioTech is a leader in the activation and mobilization of the body’s immune system to fight fatal diseases. The company is directed by people who themselves have a history of leadership in the pharmaceutical industry, a fact that has helped the company establish important agreements around the world. • Nicholas Plotnikoff, Ph.D. (Chairman) has over 20 years in the pharmaceutical industry, specifically in the fields of Pharmacology, Toxicology, and Clinical Research. Dr. Plotnikoff helped develop the immunological effects of MENK. He successfully managed the project teams that developed the N.D.A.’s on Traxene (Valium-like tranquilizer) and Cylert (non-amphetamine psychostimulant). He…

WednesdaySep 26, 2012 4:28 pm

TNI BioTech, Inc. (TNIB) Enters Agreement to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital

Earlier today, Mrs. Joyce Banda, the President of the Republic of Malawi, announced that an agreement has been signed to open an outpatient's clinic at Queen Elizabeth Central Hospital for the treatment of cancer and infectious diseases with US-based biotech firms TNI BioTech (TNIB) and GB Oncology & Imaging Group LLC (GBOIG). Chronic infectious diseases are estimated to cause more than 20 percent of all cancers in the world, including liver, cervical, and gastric malignancies. Infection-related cancers are more frequent and often more severe in people infected with HIV. Cancer patient survival rates in Malawi are abysmal due to lack…

TuesdaySep 25, 2012 10:27 am

TNI BioTech, Inc. (TNIB) Uses Immune System to Tackle Cancer, Infections, and Autoimmune Diseases

Leveraging the body’s own immune system to fight disease is one of the hottest areas in medicine. The human immune system, by its nature, is able to identify and fight disease organisms in sophisticated ways that chemicals and other traditional interventions by themselves cannot. The first human vaccines, developed in the late 1700s, represented early steps in manipulating the human immune system, and resulted in the saving of countless lives over the past two centuries. Today newly developed technologies have again opened a door to a world of immune system potential. Florida-based TNI BioTech is in the forefront of combating…

TuesdaySep 18, 2012 12:06 pm

TNI BioTech, Inc. (TNIB) is “One to Watch”

TNI BioTech is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response. The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active…

TuesdaySep 11, 2012 8:46 am

TNI BioTech, Inc. (TNIB) Enters Memorandum of Agreement to Open Pharmaceutical Plant

Today before the opening bell, TNI BioTech, a biotech company focused on combating fatal diseases through the activation and mobilization of the body’s immune system, reported that a Memorandum of Agreement has been signed involving the company and MOV-FAS S.A. to open a pharmaceutical plant in Managua, Nicaragua. TNIB has acquired a portfolio patents involving Low-Dose Naltrexone (LDN) for the treatment of HIV/AIDS, cancer and other diseases. This acquisition includes more than two decades of data showing Low Dose Naltraxone (LDN) as an effective immune system modulator, without significant toxic side effects or addicting properties, and can be administered by…

Site Search

Company Search

Tag: TNI BioTech Inc. TNIB